<DOC>
	<DOCNO>NCT01217944</DOCNO>
	<brief_summary>This study design evaluate efficacy safety two different dose regimen 0.5 mg ranibizumab give intravitreal injection comparison verteporfin PDT patient visual impairment due choroidal neovascularization ( CNV ) secondary pathologic myopia ( PM ) .</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab Patients With Visual Impairment Due Choroidal Neovascularization Secondary Pathologic Myopia</brief_title>
	<detailed_description />
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Myopia , Degenerative</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual impairment due choroidal neovascularization ( CNV ) secondary PM Best correct visual acuity ( BCVA ) study eye &gt; 24 &lt; 78 Early Treatment Diabetic Retinopathy Study ( ETDRS ) letter High myopia ( &gt; 6D ) , anteriorposterior elongation &gt; 26 mm ; posterior change compatible pathologic myopia Either lesion type study eye : subfoveal , juxtafoveal , extrafoveal Patients uncontrolled systemic ocular disease Blood pressure &gt; 150/90 mmHg History panretinal , focal/grid laser photocoagulation intraocular treatment antiVEGF vPDT study eye Intravitreal treatment corticosteroid intraocular surgery within last 3 month study eye Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pathologic myopia</keyword>
	<keyword>PM</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>CNV</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>verteporfin PDT</keyword>
</DOC>